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Human rhinovirus (HRV) infections aremajor contributors to the healthcare burden associatedwith acute exacerbations
of chronic airway disease, such as chronic obstructive pulmonary disease and asthma. Cellular responses to HRV are
mediated through pattern recognition receptors that may in part signal from membrane microdomains. We previously
found Toll-like receptor signaling is reduced, by targeting membrane microdomains with a specific liposomal
phosphatidylserine species, 1-stearoyl-2-arachidonoyl-sn-glycero-3-phospho-L-serine (SAPS). Here we explored the
ability of this approach to target a clinically important pathogen. We determined the biochemical and biophysical
properties and stability of SAPS liposomes and studied their ability to modulate rhinovirus-induced inflammation,
measured by cytokine production, and rhinovirus replication in both immortalized and normal primary bronchial
epithelial cells. SAPS liposomes rapidly partitioned throughout the plasmamembrane and internal cellular membranes
of epithelial cells.Uptakeof liposomesdidnot causecell death, butwasassociatedwithmarkedly reduced inflammatory
responses to rhinovirus, at the expense of only modest non-significant increases in viral replication, and without
impairment of interferon receptor signaling. Thus using liposomes of phosphatidylserine to target membrane
microdomains is a feasible mechanism for modulating rhinovirus-induced signaling, and potentially a prototypic new
therapy for viral-mediated inflammation.
INTRODUCTION
Human rhinoviruses (HRVs) typically cause mild infections of
the upper respiratory tract. More recently, it has become
evident that HRV infections trigger a high proportion of acute
exacerbations in airway diseases such as asthma and chronic
obstructive pulmonary disease (COPD),1 and have also been
implicated in other respiratory disorders such as pneumonia.2
Despite the frequency of these infections, there are currently no
effective specific therapies forHRV-induced inflammation, and
the multiple serotypes of HRV preclude successful vaccination.
HRVs are nonenveloped, positive sense single-stranded
RNA (ssRNA)members of the Picornaviridae family of viruses.
Presently, there are more than 150 identified HRV serotypes
divided into distinct groups; HRV-A, HRV-B, and HRV-C,
according to their phylogenetic similarity.3 HRV-A and -B
attach and gain entry to cells via the receptors intracellular
adhesion molecule 1 (ICAM-1) and low-density-lipoprotein
receptor, while the receptor for HRV-C serotypes has yet to be
identified.4-6Receptor-mediated internalization ofHRVoccurs
via membrane microdomains enriched in cholesterol or
ceramide,7 and evidence suggests that early signaling responses
toHRV infection results in activation of Src andAkt whichmay
also occur from these regions.8Membrane microdomains such
as lipid rafts are highly dynamic subdomains of the cell
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membrane, which act to facilitate protein–lipid and protein–
protein interactions and signaling.9 These domains have
important roles in promoting signaling events bymany immune
receptors, including the pattern recognition receptors (PRRs),
Toll-like receptors (TLRs).10 Infected airway epithelial cells
detect and respond to HRV via TLRs and the RNA helicases
retinoic acid-inducible gene I (RIG-I) and melanoma differ-
entiation-associated gene 5 (MDA5), activating signaling
pathways that cause the generation of pro-inflammatory
cytokines and type I interferons (IFNs). Cell surface recognition
of viral capsid proteins occurs byTLR2,11while receptors such as
TLR7/8 and RIG-I/MDA5 localize to the endosome and cytosol,
respectively, and detect single stranded (TLR7/8) or double
stranded viral RNA forms.12 Remodeling of membrane micro-
domain structure through the addition or removal of nonsterol
phospholipids has been associated with effects on signaling,13
and we have previously demonstrated that TLR signaling is
inhibited by liposomes consistingof a specific phosphatidylserine
(PS) species, 1-stearoyl-2-arachidonoyl-sn-glycero-3-phos-
pho-L-serine, which disrupted the membrane-microdomain-
dependent association of TLR4 with its co-receptor CD14.14
Herein, we examined whether therapeutic targeting of
viral-induced TLR-dependent inflammation is feasible using
SAPS liposomes. The roles of membrane microdomains have
been traditionally studied using detergent extraction and
cholesterol depletionmethods.9However, results obtained using
these techniques are hard to interpretwith precision, as detergent
extraction is highly dependent on experimental conditions, and
cholesterol depletion can result in global cellular functional
disruption.9 Recent work has also demonstrated that cholesterol
trafficking is required for effective picornavirus replication,15
therefore depleting cholesterol to modulate membrane micro-
domain function may have important consequences on viral
replication by other routes. In this study, we utilized SAPS to
explore the roles of membrane microdomains in viral signaling
processes without globally perturbing membrane structure. We
examined the stability of SAPS, created stable uniform-sized
liposomes, and determined their effects on HRV infection of
airway epithelial cells. Confocal studies revealed that SAPS was
rapidly internalized and associated with sites of importance for
HRV-induced signaling. SAPS notably impaired HRV-induced
cytokine responses, and also reduced HRV-induced IFN-b
productionand signal transducers and activators of transcription
(STAT)-1 phosphorylation. Viral replication rates were not
significantly altered, and only modest increases in viral particle
productionwere observed. Thus SAPS is a promising new tool to
study the role of membrane microdomains in viral infections,
and has the potential for future development as a novel
therapeutic strategy in the prevention of airway inflammation
within chronic pulmonary diseases such as asthma and COPD.
RESULTS
Characterization and intracellular distribution of SAPS
liposomes
We initially investigated the stability of experimental 1-stearoyl-2-
arachidonoyl-sn-glycero-3-phospho-L-serine (SAPS) liposomes
and control 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phos-
phocholine (PAPC) liposomes prepared in phosphate buffered
saline (PBS) according to the lipid hydration method.16
Blending lipids with differing hydrocarbon lengths and
saturation can alter physical properties of liposomes. We
therefore additionally determined whether incorporation of
25% 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC) to
SAPS would affect liposomal stability and activity.17 All
liposomes were of a potentially respirable mean sub-micro-
meter size, though control PAPC liposomes were larger than
SAPS and SAPSþDSPC liposomes, most likely reflecting
structural and molecular differences in the polar head group
and fatty acid chains between the molecules (Supplementary
Table S1 online).Mean liposome sizes were 203.6±48.0 nm for
SAPS and 629.6±90.7 nm for PAPC. Liposomes retained
their size distribution up to the latest tested point (28 days)
in storage at 4 1C (Supplementary Figure S1). Polydispersity
values were low (Supplementary Table S1), indicating that
formulations were homogenous in nature. Differential
scanning colorimetry was exploited to investigate the
transition temperatures of liposomes. SAPS, SAPSþDSPC,
and PAPC exhibited a single endothermic response with an
onset temperature of 17.48 1C, 18.19 1C, and 16.67 1C,
respectively (Supplementary Figure S2) consistent with
bilayer fluidity above these temperatures.18 Although DSPC
is commonly used to increase liposome stability, addition of
DSPC was not required for liposomal stability judged by sizing,
nor did it alter biological actions of SAPS (data not shown), and
hence was not routinely added to liposomes. No traces of SAPS
oxidation products were observed in a weekly mass spectro-
metric analysis over 4 weeks (Supplementary Figure S3).
HRV infection initiates intracellular signaling events
through the recognition of viral RNA structures by the
endosomal located pattern recognition receptor, TLR3.12 To
determine whether SAPS targets sites of importance for viral
signaling, we examined the intracellular distribution of
fluorescent SAPS (TopFluor-SAPS) within the bronchial
epithelial cell line BEAS-2B.19 Strikingly, TopFluor-SAPS
rapidly distributed throughout the cell within 10min, quickly
reaching endosomal compartments fromwhichTLR3 signaling
is initiated (Figure 1). Furthermore, diffusion to Golgi
membranes was also observed (Figure 2).
SAPS inhibits cytokine production induced by HRV
infection
We have previously found that SAPS inhibited inflammatory
responses to several TLR agonists through disruption of
membrane microdomains.14 Whether this translates into
biologically useful inhibition of signaling during pathogen-
mediated inflammation is unknown. We therefore determined
if SAPS would alter the roles of membrane microdomains in
cellular function and control of HRV. SAPS was either added at
4 h prior to viral infection of cells to study effects of SAPS on cell
attachment and internalization, or at several time points
post viral infection to study the effects of SAPS on early
signaling events. We examined CXCL8 and CCL5 production,
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downstream targets of nuclear factor-kappa B (NF-kB), and
interferon regulatory factor 3 (IRF-3) activation. We also
examined the production of CXCL10, a proinflammatory
chemokine with a potential role in viral-induced exacerba-
tions.20Viral titers and SAPS concentrations were as previously
described and resulted in no notable cytopathic effects.14,21
First, we assessed the kinetics of proinflammatory chemokine
production and found that CXCL10 production could be
detected from as early as 8 h post HRV infection, with
CXCL8 and CCL5 production predominately detected
from 16 h onward (Supplementary Figure S4). SAPS
reduced CXCL10, (Supplementary Figure S4e,f), CXCL8
(Figure 3b; Supplementary Figure S4a,b), and CCL5
(Figure 3d; Supplementary Figure S4c,d) production from
HRV-infected epithelial cells when added at 1 h post viral
challenge of the cells. To evaluate the efficacy of SAPS treatment
following the establishment of viral infection, SAPS was also
added 4 and 8 h after viral challenge. The addition of SAPS at 4
and 8 h post viral infection reduced cytokine production
equally well (data shown for 8 h post viral infection,
Figure 4b–g), demonstrating that, even after HRV infection
has begun to establish, SAPS addition can still act to reduce
inflammatory mediator production from bronchial epithelial
cells. The actions of SAPS were most notable upon CCL5 and
CXCL10 release. Both CCL5 and CXCL10 are considered
interferon-stimulated genes, and production is induced
following activation of an IFN-b-dependent autocrine loop.
In keeping with these data, HRV infection caused marked
induction of IFN-b mRNA relative to media controls, which
was significantly inhibited by SAPS (Figure 3f; Figure 4h,i;
and Supplementary Figure S4g,h). Type III interferons,
consisting of the three IFN-l subtypes are co-produced
with IFN-b.22 Similarly to what was observed with IFN-b
induction, SAPS treatment also significantly inhibited IFN-l1
and IFN-l2 induction (data not shown). In contrast, CXCL8,
CCL5, and IFN-b production were not significantly altered
following treatment with PAPC (Figure 3c,e,g). We next
investigated the actions of SAPS on virus internalization and
infection. Cells were pretreated with SAPS for 4 h then
subsequently infected with HRV. In the setting of treatment
before viral infection, SAPS treatment did not significantly alter
HRV-1B-induced CXCL8 (Supplementary Figure S5a,b) and
CCL5 production (Supplementary Figure S5c,d). However,
the highest concentration of SAPS tested did modestly reduce
HRV-16-induced CXCL8 and CCL5 production.
The TLR3 signaling adapter TIR domain-containing adapter
inducing IFN-b (TRIF) associates with membrane micro-
domains in the context of TLR4.23 However, little is known
about the dependence of TLR3 on membrane microdomain
signaling. To verify that SAPS treatment inhibited TLR3
signaling directly, we investigated the effect of SAPS liposome
treatment on TLR3/TRIF-dependent signaling by transfecting
epithelial cells with plasmids expressing a constitutively active
form of TRIF (DTRIF) and reporters for CXCL8 and IFN-b.12
Figure 1 Endosomal localized 1-stearoyl-2-arachidonoyl-sn-glycero-3-phospho-L-serine (SAPS). BEAS-2B cells were incubatedwith TopFluor-SAPS
(100 mgml1) for indicated time periods. Intracellular distribution of SAPS (green) partially colocalized within endosomes (EEA1/red). Images were
collected using a Nikon confocal microscope and are representative of three independent experiments. The merged image shows overlay of areas
positive for SAPS and endosome.
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DTRIF induced CXCL8 and IFN-b promoter activation, and
this was reduced by SAPS (Figure 5). The actions of SAPS were
most notable on IFN-b promoter activation (Figure 5b).
HRV-induced TLR3 activation subsequently leads to the
upregulation of the RNA helicases RIG-I and MDA5.12
Activation of inflammatory processes by these RNA helicases
is mediated by the adapter protein mitochondrial antiviral
signaling (MAVS) (also known as CARDIF, IPS-1, and VISA)
which resides at the mitochondrial outer membrane.24 The
mitochondrial membrane may also be organized to include
specific microdomains.25 Overexpression of full-length MAVS
was performed in BEAS-2B epithelial cells.24 Activation of the
CXCL8 promoter by MAVS, but not activation of the IFN-b
promoter, was inhibited by SAPS (Figure 5c,d).
Modulation of IFN-b expression by SAPS is not via direct
effects on IFN signaling pathways
Early production of IFNs activates an autocrine loop dependent
on Type I IFN receptor (IFNAR) signaling resulting in STAT1
activation. IFNAR signaling may be partly dependent on
membrane microdomain function.26 To determine if some
actions of SAPSmight be via inhibition of IFNAR,we examined
if SAPS modified HRV-induced STAT1 phosphorylation.
Induction of total STAT1 protein and STAT1 phosphorylation
was observed in HRV-infected cells at 24 h, and this
was reduced following SAPS treatment (Figure 6a–c).
The inhibitory actions of SAPS were greater at the
highest concentration tested (50 mgml 1). High
concentrations of PAPC also modestly reduced total STAT1
and STAT1 phosphorylation (Supplementary Figure S6a–c).
To ascertain whether SAPS was acting prior to, or downstream
of IFNAR, we examined whether addition of exogenous
IFN-b would recover total STAT1 protein levels and
STAT1 phosphorylation in the presence of SAPS. IFN-b
stimulation rescued the production of total STAT1 protein and
STAT1 phosphorylation in the presence of SAPS at both
concentrations tested (Figure 6d–f).
SAPS has only modest effects on viral replication
We observed significant reductions in IFN generation and
signaling in epithelial cells treated with SAPS, and therefore
determined whether this would result in increased viral
replication. HRV-infected BEAS-2B cells were quantified for
intracellular viral RNA levels by quantitative PCR (qPCR). No
significant effects on viral replication were observed following
treatment with SAPS or control PAPC when added at 1 h post
viral challenge (Figure 7a,b; Supplementary Figure S7). The
release of infective HRV-1B from BEAS-2B cells did not
significantly differ between control, SAPS-, or PAPC-treated
cells, although modest non-significant increases following
SAPS treatment were observed at 48 h (Figure 7c). Release of
HRV-16 was also modestly elevated following SAPS treatment at
24 and 48 h, again this did not reach statistical significance
(Figure 7d). The addition of SAPS 4h post viral infection
Figure 2 Golgi localized 1-stearoyl-2-arachidonoyl-sn-glycero-3-phospho-L-serine (SAPS). BEAS-2B cells were incubated with TopFluor-SAPS
(100 mgml1) for indicated timeperiods. Intracellular distribution of SAPS (green) partially colocalizedwith the golgi (GM130/red). Imageswere collected
using a Nikon confocal microscope and are representative of three independent experiments. The merged image shows overlay of areas positive for
SAPS and the Golgi.
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did not notably effect viral replication (data not shown),
although moderate increases in HRV-16 replication were
detected at SAPS concentrations of 50mgml 1 at 24 h
only. Replication did not differ significantly between control
or SAPS-treated cells, when SAPS was added at 8 h post viral
infection, although moderate non-significant decreases in viral
replication were detected at 48 h following SAPS treatment
(Figure 8b).
Figure 3 1-Stearoyl-2-arachidonoyl-sn-glycero-3-phospho-L-serine (SAPS) modulates human rhinovirus (HRV)-induced cytokine production. (a)
Experimental design. BEAS-2B cells infectedwithHRV (MOI 3/TCID50 perml 1 10
7) were treatedwith SAPS or 1-palmitoyl-2-arachidonoyl-sn-glycero-
3-phosphocholine (PAPC)at thedoses indicated. After 24 h,CXCL8 (b,c) orCCL5 (d,e) releaseweremeasured, and IFN-bmRNAexpressionquantified
and presented as total IFN-bmRNAcopies per 1 mgRNAnormalized toGAPDHexpression (f,g). Data shown aremean±s.e.m. (n¼11 forb, n¼ 9 for c,
and n¼ 6 for d, f, and g). Significant differences are indicated by *Po0.05, **Po0.01 ***Po0.001, and ****Po0.0001.
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Figure 4 1-Stearoyl-2-arachidonoyl-sn-glycero-3-phospho-L-serine (SAPS) modulates established human rhinovirus (HRV)-induced cytokine
production. (a) Experimental design. BEAS-2B cells infected with HRV (MOI 3/TCID50 per ml 1 10
7) were treated with SAPS at 8 h post-viral
internalization at the doses indicated. After 24 h (b, d, f, h) or 48 h (c, e, g, i), CXCL8 (b, c), CCL5 (d, e), and CXCL10 (f, g) release were measured, and
IFN-bmRNA expression quantified and presented as total IFN-bmRNA copies per 1 mg RNA normalized to GAPDH expression (h, i). Data shown are
mean±s.e.m. (n¼ 3). Significant differences are indicated by *Po0.05, **Po0.01, ***Po0.001, and ****Po0.0001.
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Figure 5 1-Stearoyl-2-arachidonoyl-sn-glycero-3-phospho-L-serine (SAPS)modulates TRIF- andMAVS-dependent activation of the CXCL8 and IFN-
b promoters. BEAS-2B cells were transfectedwith plasmids encodingDTRIF andMAVS.After 6 h, transfected cells were treatedwith the indicatedSAPS
concentrations and cell lysates were generated at 24 h.DTRIF (a, b) or MAVS (c, d) induced CXCL8 (a, c), and IFN-b (b, d) reporter activation relative to
empty vector control pUNO1wasmeasured. Data shown aremean±s.e.m. (n¼ 2 for a andb, and n¼ 5 for c andd). Reporter data are presented as fold
induction vs. control. Significant differences are indicated by *Po0.05.
Figure 6 The actions of 1-stearoyl-2-arachidonoyl-sn-glycero-3-phospho-L-serine (SAPS) are not through modulation of the Type I IFN receptor
(IFNAR). BEAS-2B cells were infected with human rhinovirus (HRV) (MOI 3) (a-c), then treated with SAPS; or pre-treated with SAPS for 1 h prior to the
addition of IFN-b (10 and 100 ngml1) (d-f). Whole-cell lysates were collected at 24 h. A representative blot of three (c) or four (f) independent
experiments is shown. Data shown are mean±s.e.m. (n¼3 for a and b, and n¼ 4 for d and e). Significant differences are indicated by **Po0.01,
***Po0.001, and ****Po0.0001.
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PRR is not altered by SAPS
Activation of PRRs following HRV infection results in the
downstream activation of transcription factors such as IRF-3.
Given the reduction in IFN production consequent upon SAPS
treatment of virally infected cells, we determined whether there
was also suppression of PRR and IRF expression. HRV
infection induced TLR3, RIG-I, MDA5, IRF-1, and IRF-7
relative to media controls, and this was not inhibited by SAPS
treatment (Supplementary Figures S8 and S9). Expression of
IRF-3 and MAVS were unaltered in the presence or absence of
HRV or SAPS.
SAPS regulated HRV-induced inflammatory responses in
normal and diseased primary bronchial epithelial cells
We next examined the actions of SAPS on HRV infection of
human primary bronchial epithelial cells (PBECs). Compared
with BEAS-2B cells, SAPS exerted less inhibition of CXCL8 but
very marked inhibition of CCL5 production (Figure 9). No
significant effects on viral replicationwere observedwhen SAPS
was present at concentrations of 25 or 50 mgml 1 (Figure 9c),
but moderate increases in viral replication were detected at
SAPS concentrations of 10 mgml 1. HRV infections are
important triggers of acute episodes within chronic diseases
such as asthma and COPD. Pro-inflammatory mediators such
as CXCL8 and CCL5 generated during infection potentially
perpetuate underlying chronic inflammation,27,28 while pre-
existing allergic inflammation may be enhanced by HRV
infection.29We hypothesized that SAPS would also be effective
in disease, and examined the actions of SAPS onHRV infection
of human PBECs obtained from people with COPD. Epithelial
cells from people with COPD were more susceptible to HRV
infection and SAPS treatment. Accordingly, cells were infected
with HRV-1B at a reduced viral titer (1.3 105 TCID50 per ml)
and treated with SAPS concentrations (10 and 20 mgml 1) that
resulted in cytopathic effects that were comparable to those
observed in normal PBECs. SAPS reduced CXCL8 (Figure 10a)
and CCL5 (Figure 10b) production from HRV-1B-infected
epithelial cells, with the actions of SAPSmost notable for CCL5
release. No significant effects on viral replication were observed
(Figure 10c). Human primary airway epithelial cells cultured at
air–liquid interface (ALI) are regarded to better represent the
characteristics of normal respiratory epithelium in vivo.30,31We
therefore examined the uptake of TopFluor-SAPS within
PBECs differentiated at ALI. PBECs cultured at ALI expressed
markers of basal cell differentiation such as ciliated bronchial
epithelium 1 (CBE1) and Mucin 5B (MUC5B) as shown by
reverse-transcriptase PCR (RT-PCR) (Supplementary Figure
S10a), andb-Tubulin as shown by immunofluorescence confocal
microscopy (Supplementary Figure S10b) confirming that the
primary cells had effectively differentiated into a mucociliary
phenotype.32 TopFluor-SAPS internalized into the cell as
quickly as 30min post application (data not shown).
Within 180min, most of the TopFluor-SAPS diffused to
intracellular regions as determined by confocal Z-stack imaging
(Supplementary Figure S11).
DISCUSSION
Respiratory viruses, such as HRVs are important drivers of
acute exacerbations of chronic pulmonary diseases. Our
previous work has established that inhibition of TLR signaling
Figure 7 1-Stearoyl-2-arachidonoyl-sn-glycero-3-phospho-L-serine (SAPS) treatment has modest effects on viral replication. BEAS-2B cells were
infected with human rhinovirus (HRV) (MOI 3/TCID50 per ml 1 10
7), and treated with (a) SAPS or (b) 1-palmitoyl-2-arachidonoyl-sn-glycero-3-
phosphocholine (PAPC). Intracellular viral RNA expression was quantified at 24 h, with data presented as the total intracellular viral RNA copies per 1 mg
RNA. Viral particle release into the supernatant was quantified at the indicated time periods following liposome treatment (50 mgml1) (c, d). Data shown
are mean±s.e.m. (n¼ 6 for a and n¼ 4 for b–d). Significant differences are indicated by *Po0.05 and **Po0.01.
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by a phosphatidylserine species (SAPS) occurs through a
mechanism that is dependent upon the disruption of TLR
signaling complexes within membrane microdomains.14
Various lines of evidence show that membrane microdomains
are sites of attachment and cell entry for HRV, and that early
cellular inflammatory signaling is mediated from such
domains.7,8,33 Furthermore, viral cell entry requires acidifica-
tion and maturation of endosomes,34 TLR3 signals from
endosomes and is implicated in recognition of responses to
HRV,11,12 and membrane reorganization of the cell is required
for viral replication.35 These studies raise the possibility that
SAPS could potentially alter HRV infectivity, inflammatory
signaling, and replication by targetingmembranemicrodomain
function, and as such be useful as a treatment for HRV
infection.
In this study, we reveal that SAPS liposomes can regulate
innate immune responses activated by HRV infection. The
addition of SAPS liposomes at various times following viral
infection suppressed the release of the proinflammatory
cytokines, CXCL8 and CXCL10, as well as the interferon-
stimulated gene CCL5/RANTES from epithelial cell lines and
normal and diseased primary human bronchial epithelial cells.
In keeping with reductions in CCL5 production, viral-induced
type I IFN generation was also reduced, with the highest tested
concentration of SAPS also inhibiting STAT1 induction and
phosphorylation. Although reductions in IFN production were
observed, this did not appear to affect viral replication, as in
most cases viral replication was unimpeded by liposome
treatment in the BEAS-2B epithelial cell line and in human
PBECs. Furthermore, similar replication characteristics were
observed regardless of whether cells were from normal
individuals or people with COPD. This suggests that the
potential mechanism of action of SAPS is not via direct
interference of virus attachment and internalization, and SAPS
is therefore not preventing subsequent cycles of viral infection.
Indeed SAPS treatment before viral challenge with removal of
Figure 9 1-Stearoyl-2-arachidonoyl-sn-glycero-3-phospho-L-serine
(SAPS) selectively modulates human rhinovirus (HRV)-induced cytokine
production from primary bronchial epithelial cells (PBECs). PBECs were
infected with HRV (MOI 3/TCID50 per ml 110
7), followed by SAPS (a–c)
treatment at the doses indicated. After 48 h, CXCL8 (a) and CCL5 (b)
release were measured, and intracellular viral RNA expression was
quantified (c) with data presented as the total intracellular viral RNAcopies
per 1 mg RNA. Data shown are mean±s.e.m. (n¼4) with each replicate
performedon independent donors. Significant differences are indicated by
*Po0.05, **Po0.01, *** and ****Po0.0001.
Figure 8 1-Stearoyl-2-arachidonoyl-sn-glycero-3-phospho-L-serine
(SAPS) addition 8 h post virus internalization does not effect viral
replication. BEAS-2B cells were infected with human rhinovirus (HRV)
(MOI 3/TCID50 per ml 1 10
7), and treated with SAPS at 8 h post virus
internalization. Intracellular viral RNAexpressionwasquantified at 24 h (a)
and 48 h (b) with data presented as the total intracellular viral RNA copies
per 1 mg RNA. Data shown are mean±s.e.m. (n¼3).
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liposomes immediately before viral infection further validates
this conclusion, as it does not substantially diminish
HRV-induced CXCL8 and CCL5 induction. In addition,
although studies indicate that minor group and major group
rhinoviruses enter cells through distinguishable mechanisms,
and uncoat and infect from distinct endosomal popula-
tions,33,36,37 no notable differences were observed between
the two HRV serotypes studied here. Another possible
mechanism of action is that part of the reduction in CCL5
production is due to the direct disruption of type I IFN
autocrine actions by SAPS, given that the downstream effectors
of the IFNAR, JAK1, and STAT1 associate with caveolar
regions; a specialized sub-domain of membrane lipid rafts.38
However, our in vitro studies rule out this possibilty as
exogenous IFN-b induced STAT1 in the presence of SAPS.
Furthermore, our data also demonstrate that antiviral defense
through the activation of antiviral effectors is still occurring, as
inducible and constitutive PRR and IRF expression was not
inhibited by SAPS, and inhibition of IFN production did not
result in enhanced viral replication. It should be noted that
variations on the dependence of IFN to induce interferon-
stimulated genes have been reported.39–41 Our data provide
strong evidence that IFNAR is for the most part not dependent
on membrane microdomains and that reductions in CCL5
production are likely a result of SAPS acting further upstream to
diminish IFN production or p65 activity.42
The PRR, TLR3 is crucial for mediating responses to
rhinovirus,12 and is localized to the endosome. To determine if
disruption of TLR3 signaling by direct actions of SAPS was a
feasible mechanism of inhibition, we studied the intracellular
trafficking of SAPS. Fluorescent SAPS partitioned rapidly
through both basal and differentiated epithelial cells, appearing
to quickly reach intracellular regions. Such a rapid uptake and
distribution of phosphatidylserine species through the cell has
been observed in recent work from another group,43 and is in
keeping with older data obtained in fibroblasts.44 The
mechanisms of uptake of SAPS have yet to be characterized,
though appear to be an active phospholipid-specific pathway.44
Further supporting potential direct targeting of the TLR3
signaling pathway, we also observed a reduction in
TRIF-dependent signaling following SAPS treatment. When
HRV infects epithelial cells, TLR3 signaling is followed by
activation of the RNA helicases, RIG-I, andMDA5. Membrane
microdomains have been detected within endosomal and
mitochondrial membranes, the sites at which TLR3/RNA
helicase signaling adapters dock respectively25,45 To determine
whether SAPS targeted RNA helicase signaling pathways, we
also studied effects on MAVS-dependent signaling. Interest-
ingly, SAPS reduced MAVS-dependent activation of CXCL8,
without impairing IFN-b activation. Very recent work has
shown that binding of eukaryotic elongation factor 1 Bg
(eEF1Bg) to MAVS at the mitochondrial membrane positively
regulates the activation of the transcription factor NF-kB and
pro-inflammatory cytokines such as CXCL8.46 One potential
explanation for our observations is that SAPS is acting to
modulate signaling at the mitochondrial membrane, thereby
preventing recruitment of eEF1Bg. In addition,MAVShas been
shown to reside on peroxisomes as well as at the mitochondrial
membrane, with variations in antiviral signaling from each
subcellular compartment.40 Our data suggest the possibility
that activation of IFN pathways by MAVS is dependent upon
downstream protein–protein interactions that are either in
domains not targeted by SAPS, or are independent of
microdomain function. Furthermore, it is feasible that SAPS
Figure 10 1-Stearoyl-2-arachidonoyl-sn-glycero-3-phospho-L-serine
(SAPS) modulates human rhinovirus (HRV)-induced cytokine production
from primary bronchial epithelial cells (PBECs) isolated from chronic
obstructive pulmonary disease (COPD) patients. PBECs isolated from
people with COPD were infected with HRV (MOI 0.1/TCID50 per ml
1.3 105), followed by SAPS (a–c) treatment at the doses indicated. After
48 h, CXCL8 (a) and CCL5 (b) release were measured, and intracellular
viral RNA expression was quantified with data presented as the total
intracellular viralRNAcopiesper 1 mgRNA.Data shownaremean±s.e.m.
(n¼ 3) with each replicate performed on independent donors. Significant
differences are indicated by *Po0.05.
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only selectively targets particular components of MAVS
signaling. As our data above show that MAVS activation of
IFN is not inhibited by SAPS, these data imply that themajority
of the induction of IFN by HRV over the time course studied
here is mediated through TLR3 signaling. Consistent with
previous studies,14 we again confirm that SAPS does not result
in a global disruption of receptor-mediated signaling, with anti-
viral responses selectively suppressed by SAPS. Furthermore,
preservation of the induction of downstream antiviral PRRs in
response to HRV infection was observed, supporting our view
that potential targets of SAPS are further upstream.
The use of SAPS as a potential anti-inflammatory has several
potential advantages. First, it is a completely naturally
occurring phospholipid,14 which has so far proved non-toxic
in bacterial and viral animal challenge studies (unpublished
observations). Furthermore, as it is naturally occurring, it will
be processed through normal physiological mechanisms,47 and
is unlikely to have adverse drug interactions. Second, our
current in vitro studies demonstrate that all liposomes prepared
throughout the study showed size characteristics within the
submicrometer respirable range (o5mm)48 thus supporting a
potential therapeutic application for delivery to the respiratory
tract in a nebulized form. Other studies indicate that liposomal
size stability has important effects on the biological activity of
the liposome formulations, with oxidation during storage a
significant influencing factor.49,50 Our liposomes were stable
for more than 1 month’s storage, and analyses revealed no
notable traces of SAPS oxidation. Moreover, although
liposomal characteristics can be significantly affected by the
choice of lipid species, with vesicle size notably influencing
biodistribution,51 the addition of the lipidDSPC to SAPSwas of
no added benefit, suggesting that SAPS liposomes alone would
be stable enough to be made in advance of any clinical use.
Third, the stability and simplicity of SAPS also make it an
appealing candidate therapeutic in terms of cost. Last, given
that antiviral properties have been demonstrated for other lipid
species,52,53 it is feasible that delivery of SAPS in combination
with other lipid components may enhance its potency as both
an anti-inflammatory and anti-viral agent. Although our
research currently focuses on the use of empty liposomes to
modulate airway inflammation, the packaging of these liposomes
to contain IFN is also a possibility. Especially as our data
demonstrates that exogenous IFN can still activate downstream
signaling via the IFNAR in the presence of SAPS. Given that our
data demonstrates a reduced ability to produce interferon, albeit
without adverse consequences on viral replication, this may be
advisable. Several studies have implicated defective IFN induc-
tion as a potential mechanism for driving virus-induced asthma
exacerbations,54,55 although, others have failed to reproduce
these results.56,57 We could conceivably supplement the anti-
inflammatory actions of SAPS with IFN. Thus activating
anti-viral signaling pathways that would limit viral replication,
and subsequent spread of viral infection. Such considerations are
the potential subject of future experiments.
Although SAPS has appreciable therapeutic potential, there
is reason for caution. Although key experiments were
conducted in undifferentiated normal and diseased human
PBECs, a large proportion of the data was generated using the
immortalized epithelial cell line, BEAS-2B in an acute lungmodel.
Thus the results may not fully resemble what may occur in vivo
within chronic lung diseases such as asthma and COPD, and the
wider implications of using such liposomes in more complex
models are unclear. Furthermore, despite initial characterization
studies indicating potential liposome delivery to the lung, the
distribution anddepositionof these liposomes in vivohas yet tobe
examined. Future studies may involve studying the action of
SAPS in a relevant chronic inflammation model that reproduces
many of the features of asthma or COPD.58,59
Nevertheless, our data show that SAPS liposomes have the
ability to modulate HRV-induced inflammatory signaling
in vitro, without significant effects on viral replication in both
normal and diseased epithelial cells. We have previously also
demonstrated that SAPS can efficiently disrupt communicative
dialog between cocultures of tissue cells and leukocytes in
response to TLR agonists in vitro.14 Thus while a continued
understanding of the effects of SAPS liposomes on other
epithelial cell functions and on the development of adaptive
immunity is clearly essential for the potential development of
SAPS as an anti-inflammatory therapy to regulate airway
inflammation, SAPS liposomes represent an exciting ther-
apeutic prospect and a new tool to explore membrane
microdomain roles in regulating viral signaling processes.
METHODS
Cell culture. BEAS-2B epithelial and HeLa OHIO cell lines were
obtained from ATCC (LGC Standards, Teddington, UK) and ECACC
(Sigma-Aldrich, Dorset, UK), respectively, and maintained as pre-
viously described.21 PBECs isolated from healthy humans were
purchased fromPromocell (Heidelberg, Germany) andPBECs isolated
from three patients with COPD were purchased from Lonza (Basel,
Switzerland). Cells were maintained as previously described.60
Differentiation of PBECs. Normal PBECs (Promocell) were initially
cultured in BEGM medium (Promocell) as previously described.60
Cells were obtained from one individual donor, seeded into T25 flasks,
and subcultured with Trypsin-EDTA. At confluency, PBECs were
subcultured with Trypsin-EDTA and re-suspended in ALI media
consisting of 50% DMEM (Invitrogen, Paisley, UK), 50% BEGM plus
all pack supplements except retinoic acid (Promocell), retinoic acid
(100 nM) (Sigma-Aldrich), and BSA (1.5mgml 1) (Sigma-Aldrich).
Cultures were seeded at 0.5 106 cells perml onto the apical surface of
Collagen I (Becton Dickinson, Oxford, UK) coated transwell PET
inserts with 0.4 mmpore size (FALCON; BectonDickinson) and placed
in 24-well flat-bottomed plates with 0.75ml of ALI media in the basal
and 0.25ml of ALI media in the upper compartments. Media in both
compartments was changed daily until cell confluency was reached.
Media was removed at confluency and cells were left exposed to air, to
generate an ALI. The apical surface was washed with 200 ml of sterile
PBS to remove mucus and basal media changed every 48 h until the
cells underwentmucociliary differentiation. Differentiation of the cells
was assessed by, immunofluorescence (IF) using staining for the
structural ciliamarkerb-tubulin, and byRT-PCR forCBE1, SPLUNC1
and MUC5B, markers shown to be upregulated during the process of
differentiation.32 Cells were used for experiments following culture at
ALI for 21 days.
GenerationofHRVstocks. HRVminor group serotype 1B (HRV-1B)
and major group serotype 16 (HRV-16) were obtained from ATCC
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and viral stocks (average 2.5 107 TCID50 per ml) generated by
infecting HeLa Ohio cells as previously described,21 and titered by
determining the development of cytopathic effect (CPE).
VirusCPEassay. Subconfluent Ohio HeLa cells in 96-well plates were
exposed to serial dilutions of infectious supernatants. Development of
a CPE was visualized after 4 days. Assays were performed in eight
replicate wells, and endpoint titers were defined by the highest dilution
at which CPE was observed in 50% of the wells (TCID50).
Preparation of phospholipid liposomes. The lipids 1-stearoyl-2-
arachidonoyl-sn-glycero-3-phospho-L-serine, 1-palmitoyl-2-arachidonoyl-
sn-glycero-3-phosphocholine, 1,2-distearoyl-sn-glycero-3-phosphocholine
and TopFluor-SAPS were purchased from Avanti Polar Lipids (Alabaster,
AL). Liposomes were prepared using the lipid hydration method.16
Liposomes were stored at 4 1C in glass vials.
Liposome characterization. Liposomal size was measured using
photon correlation spectroscopy using a ZetaPlus (Brookhaven
Instrument Corporation, Holtsville, NY). The phase transitional
behavior of liposomes was studied using a differential scanning
calorimeter (Diamond DSC; PerkinElmer, MA). Stability of free and
liposomal SAPS was analyzed by direct infusion mass spectrometry
(4000 QTRAP LC/MS/MS). Liposomal and free SAPS were diluted in
methanol to 100- and 1,000-fold, respectively. Three replicates were
prepared for each sample type. These were directly infused at 10 ml per
min on a QTRAP mass spectrometer (4000 QTRAP LC/MS/MS), to
monitor chemical stability of SAPS by analyzing its molecular mass
(810.6 a.m.u., [MH] ) in negative ionization mode. Samples were
analyzed weekly over 4 weeks and were stored at 4 1C. The MS
conditions were as follows: source temperature 0 1C, ion source gas 1
(GS1) 15, GS2 0, declustering potential (DP)  60V, entrance
potential (EP)  10V and spray voltage  4.5 kV. Briefly, full scan
spectra was acquired in the first quadrupole (Q1) over 500–
1,000 a.m.u., at unit mass resolution and profile mode, for 2 s and
summed for 10 scans.
Cell treatment and infection. Epithelial cells were either pre-treated
with liposomes for 4 h before viral infection, or added at 1, 4, or 8 h post
infection. Epithelial cells were infected with HRV at the indicated
TCID50 per ml for 1 h, as described previously,
21,60 following which
virus was removed, cells were washed, and 1ml infection medium
containing liposomes was then added to the appropriate wells.
Epithelial cells stimulated with recombinant cytokine were pre-treated
with liposomes for 1 h before the addition of IFN-b (PeproTech EC,
London, UK). Liposomes remained present throughout. Cell
supernatants, lysates or mRNA were collected at the appropriate time
points and stored at  80 1C.
Transient transfections of BEAS-2B cells with plasmid DNA.
Transient plasmid transfection was carried out as previously
described42 using constitutively active TRIF, MAVS, or the pUNO1
control vector (Invivogen, France), 0.25 mg CXCL8 or IFN-b reporter,
0.1mg of Renilla plasmid (Promega, Southampton, UK), and Superfect
transfection reagent (Quiagen, Manchester, UK) kindly provided by
Dr MR Edwards (Imperial College, London, UK). At 5 h post
transfection, cells were washed and treated with SAPS at the indicated
concentrations. Lysates were collected at 24 h, and luciferasemeasured
according to the dual luciferase protocol (Promega) using a Berthold
luminometer (Berthold Technologies, Herts, UK) with data expressed
as ratios of firefly over renilla luciferase.
RT-PCRandqPCR. RNAwas prepared from cell lysates and converted
to cDNA as previously described.60 RT-PCR was carried out using
GoTaq Flexi DNA polymerase (Promega) and primers specific for
TLR3, RIG-I, MDA5, MAVS, IRF1, IRF3, IRF7, CBE1, SPLUNC1,
MUC5B, GAPDH, and b-ACTIN. qPCR was carried out as descri-
bed12,21 using primers and probes specific toHRV, IFN-b, IFN-l1, and
IFN-l2 (Sigma-Aldrich), and TaqMan gene expression assay probe set
specific to GAPDH (Hs00182082_m1) (Applied Biosystems, Paisley,
UK). PCR reactions were performed on an ABI7900 TaqMan (Applied
Biosystems), with the target genes quantified against a standard curve of
plasmids containing known copy numbers of target genes. IFN-b, IFN-
l1, and IFN-l2 expression was subsequently normalized to GAPDH.
Immunofluorescence. For localization studies, BEAS-2B cells were
seeded onto collagen-coated microchamber culture slides (MatTek
Corporation, Ashland, MA) and grown overnight. Cells were sub-
sequently incubated with TopFluor-SAPS (100 mgml 1) (Avanti
Polar Lipids) for the indicated time periods. For studies examining
SAPS uptake into differentiated epithelial cells, PBECswere cultured at
ALI as described above and subsequently incubated with TopFluor-
SAPS (25 mgml 1) (Avanti Polar Lipids) for 30, 60, 120, and 180min.
Cells were then fixed with 4% paraformaldehyde, permeabilized with
PBS containing 0.1% saponin and 5% normal goat serum for 60min,
and incubated with primary antibodies (EEA1 and GM130; BD
Biosciences, Oxford, UK or b-Tubulin; Sigma-Aldrich) diluted 1:100
in PBS containing 0.1% saponin and 1% bovine serum albumin
overnight at 4 1C directly on the microchamber culture slide or
transwell membrane. After extensive washing, cells were incubated
with AlexaFluor 555-conjugated secondary antibodies diluted 1:1,000
(Molecular Probes, Paisley, UK) for EEA1 and GM130, or AlexaFluor
488-conjugated secondary antibody diluted 1:200 (Molecular Probes)
for b-Tubulin at RT for 60min in the dark. Cellular DNA was stained
with 4,6-diamidino-2-phenylindole (DAPI) (Molecular Probes). Cells
were washed, mounted with ProLong Antifade Kit (Molecular Probes)
and imaged on a Nikon A1 confocal microscope (Nikon Instruments,
UK) and viewed using Image J software (Version 1.44o; NIH).
Western blot. Western blot analysis was conducted as previously
described.14 Samples were probed with anti-phospho-STAT1,
anti-STAT1 total (Abcam, Cambridge, UK), or anti-actin (Sigma-
Aldrich). Densitometric analysis was carried out using Image J
software (Version 1.44o; NIH).
Statistical analysis. All data are presented as mean±s.e.m. (where
appropriate) of at least three independent experiments. Data were
analyzed using the statistical tests stated using Prism 6.0 software
(GraphPad Inc., La Jolla, CA). Multiple comparisons were performed
by using two-way ANOVA and Bonferroni’s post test. Experiments
using transfection with plasmids were analyzed by one-way ANOVA
and Tukey’s post test. Significant differences are indicated by by
*Po0.05, **Po0.01 ***Po0.001, and ****Po0.0001.
SUPPLEMENTARYMATERIAL is linked to the online version of the paper
at http://www.nature.com/mi
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